Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Maybe early 2019?Interesting but a shame there's no more details. I wonder when they're aiming to publish?
Okay found it. It's a post also by @HufsamorI seem to remember seeing another article or video about similar antibody research recently but can't remember where. I'm glad to see it being replicated.
A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS (n?=?25) and matched control (n?=?25) sera were obtained from a Canadian study. ME/CFS (n?=?25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker.
I would have if I could, but it seems I have forgotten how I did it?suggest you update the title to something more descriptive like "Antibody Biomarker Discovery Research at Bateman Horne Center using technology from Serimmune".
I changed it. I'll have to check and see how it's ordinarily done and will get back to you so you could do it yourself in the future.I would have if I could, but it seems I have forgotten how I did it?
May you guide me?
I know the feeling!@Mary thanks...
I've done it myself ones before...
So I'm afraid it doesn't help if you explain now, next time I need it, I have probably forgotten again